Spanish Diabetes Society (SED) recommendations for the pharmacologic treatment of hyperglycemia in type 2 diabetes: 2018 Update

• Published in: Endocrinología, diabetes y nutrición. Vol. 65; no. 10; pp. 611 - 624
• Main Authors: Gomez-Peralta, Fernando, Escalada San Martín, Francisco Javier, Menéndez Torre, Edelmiro, Mata Cases, Manel, Ferrer García, Juan Carlos, Ezkurra Loiola, Patxi, Ávila Lachica, Luis, Fornos Pérez, Jose Antonio, Artola Menéndez, Sara, Álvarez-Guisasola, Fernando, Rica Echevarría, Itxaso, Girbés Borrás, Juan
• Format: Journal Article
• Language: English
• Published: Elsevier España, S.L.U 01-12-2018
• Subjects: Cardiovascular risk; Complejidad; Complexity; Cost; Coste; Diabetes tipo 2; Endocrinology and Metabolism; Hipoglucemia; Hypoglycaemia; Nefroprotección; Nephroprotection; Riesgo cardiovascular; Tratamiento; Treatment; Type 2 diabetes; Type 2 diabetes; Hypoglycaemia; Diabetes tipo 2; Hipoglucemia; Cost; Complexity; Nefroprotección; Treatment; Cardiovascular risk; Riesgo cardiovascular; Nephroprotection; Tratamiento; Complejidad; Coste
• ISSN: 2530-0180; 2530-0180
• DOI: 10.1016/j.endien.2018.11.010

Abstract Type 2 diabetes mellitus (DM2) has become a problem of global dimensions by their high and growing prevalence worldwide and the personal and economic costs associated with it. Correct treatment can reduce mortality and associated complications. New concepts have recently been included in routine clinical practice and have changed the algorithm of DM2 pharmacological therapy. Therefore, the Spanish Society of Diabetes (SED) entrusted to the Working Group of Consensus and Clinical Guidelines an update of the 2010 document Recommendations for Pharmacological Treatment of Hyperglycemia in Diabetes type 2. Novel aspects include nine characteristics to describe each drug group: efficiency, the risk of hypoglycemia, effects on body weight, the demonstrated effect in cardiovascular risk, nephroprotection, limitation of use in renal insufficiency, the rate of secondary effects, complexity and costs. Additionally, the document details combination options, and develop the start and adjustment of available injectable therapies.